Life Insurance In Force of Alignment Healthcare, Inc. – NASDAQ:ALHC
This article provides financial information for Alignment Healthcare, Inc. (NASDAQ:ALHC), specifically focusing on its "Life Insurance In Force" metric. The content highlights the company's stock market presence on Nasdaq and directs users to various financial data, news, and community sections.
Medicare Advantage Company Alignment Healthcare Shows Huge, Unusual Call Option Activity
Alignment Healthcare (ALHC), a Medicare Advantage company, is experiencing significant unusual call option activity, particularly at the $20.00 strike price expiring in August. This suggests that large institutional investors see the stock as undervalued despite a recent drop from its Q1 peak, betting on a substantial price increase. The bullish sentiment is supported by the company's strong Q1 revenue and adjusted EBITDA growth, along with conservative future projections that imply a higher underlying value and price target.
Alignment Healthcare (ALHC) executive Mark D. Kent files initial Form 3
Alignment Healthcare, Inc. (ALHC) has filed an initial Form 3 for Mark D. Kent, establishing him as a reporting officer (President - MSO) of the company. This filing indicates that Kent does not currently own any securities and is not a "ten percent owner." The Form 3 serves as an initial public declaration of his insider status without reporting any beneficial ownership or transactions at this time.
Is Alignment Healthcare’s (ALHC) Index Debut and Leadership Shuffle Reframing Its Long-Term Strategic Ambitions?
Alignment Healthcare (ALHC) recently underwent a leadership reshuffle, with founder John Kao becoming Chairman and new senior hires taking COO and MSO President roles. Concurrently, the company was added to the S&P SmallCap 600 and S&P Composite 1500, potentially increasing its investor base and visibility. These changes occur as Alignment Healthcare aims for significant revenue and earnings growth by 2029 through its tech-enabled Medicare Advantage model, though management of medical costs and regulatory risks remain critical for its profitability.
Alignment healthcare president Dawn Maroney sells $482,565 in shares
Dawn Christine Maroney, President of Alignment Healthcare, Inc., sold 30,000 shares of company common stock for a total of $482,565 on May 15, 2026, under a pre-arranged trading plan. She also gifted 21,500 shares in two separate transactions to a family member and a charitable fund. These transactions come as the company recently exceeded Q1 2026 earnings expectations and announced leadership changes.
Alignment healthcare president Dawn Maroney sells $482,565 in shares
Dawn Maroney, President of Alignment Healthcare, Inc., sold 30,000 shares of company common stock for $482,565 on May 15, 2026, under a Rule 10b5-1 trading plan. Additionally, Maroney gifted a total of 21,500 shares to a family member and a charitable donor-advised fund. Despite the stock's recent decline, Alignment Healthcare's shares are considered undervalued by InvestingPro, and the company reported strong Q1 2026 earnings and leadership changes.
Alignment Healthcare (ALHC) president sells 30,000 shares and gifts 21,500
Alignment Healthcare (ALHC) President Dawn Christine Maroney reported selling 30,000 shares in an open-market transaction at a weighted-average price of $16.0855 per share, under a Rule 10b5-1 plan. Additionally, she gifted a total of 21,500 shares, comprising 20,000 to a family member and 1,500 to a charitable donor advised fund. Following these transactions, Maroney directly holds 977,313 shares of the company.
Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Alignment Healthcare, Inc. (NASDAQ: ALHC) announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 in Miami, Florida, on June 9, at 10:40 a.m. EDT. A webcast and replay of the presentation will be available on their investor relations website. The company champions senior care, aiming to provide high-quality, low-cost care to Medicare Advantage members.
Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Alignment Healthcare (NASDAQ: ALHC) announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 9 in Miami, Florida. A webcast of the presentation will be available on the company's investor relations website. Alignment Healthcare focuses on providing high-quality, low-cost senior care through its Medicare Advantage plans, leveraging a customized care model and technology.
Assessing Alignment Healthcare (ALHC) Valuation After Recent Share Price Weakness
Alignment Healthcare (ALHC) has experienced recent stock price weakness, with shares down significantly over the past day, week, and month, though long-term holders still show gains. Despite reporting substantial revenue and net income, the company is considered undervalued by a narrative fair value of $25.50 against its last close of $15.73. This valuation hinges on the expectation of future growth, margin expansion, and reduced SG&A expenses driven by its technology-enabled care model and market expansion, though risks like tighter Medicare Advantage rules could challenge these assumptions.
Alignment Healthcare’s Seventh PQA Award And The Medicare Advantage Story
Alignment Healthcare (ALHC) has received its seventh PQA Excellence in Quality Award, recognized for perfect scores in Medicare Advantage prescription drug quality measures, emphasizing its commitment to senior medication adherence and safety. This award comes amid a leadership restructuring, reinforcing the company's focus on member-centric care and operational depth as it scales within the Medicare Advantage market. Investors should consider the balance between regulatory risks and the rewards of sustained quality and strengthened leadership in ALHC's growth narrative.
Alignment Healthcare Joins S&P SmallCap 600; Shares Gain 7.8% - News and Statistics
Alignment Healthcare (NASDAQ:ALHC) saw its shares climb 7.8% after the announcement that it would be added to the S&P SmallCap 600 index, replacing Sun Country Airlines Holdings. This inclusion is generally positive as index funds and ETFs tracking the S&P SmallCap 600 are required to purchase shares, increasing demand. Despite today's gain, the stock is down 8.8% year-to-date and trades 22.5% below its 52-week high.
General Atlantic (NASDAQ: ALHC) reports 308,852-share position in Alignment Healthcare
General Atlantic and its affiliated entities have reported a shared beneficial ownership of 308,852 shares of Alignment Healthcare, Inc. (NASDAQ: ALHC) Class A common stock. This position represents 0.1% of the company’s 206,733,823 outstanding shares as of April 27, 2026, and is detailed in an amended Schedule 13G/A filing. The ownership is distributed among several General Atlantic entities, with shared voting and dispositive power.
Alignment Health Plan Recognized as One of Four Medicare Advantage Prescription Drug Plans in the U.S. for 2026 Excellence in Quality
Alignment Healthcare, Inc. (NASDAQ: ALHC) has been recognized by the Pharmacy Quality Alliance (PQA) for excellence in quality for its Medicare Advantage prescription drug (MAPD) plan for the seventh time. Alignment Health Plan is one of only four MAPD plans nationally to receive the 2026 PQA Laura Cranston Excellence in Quality Award, achieving perfect 5-star ratings across all five PQA medication measures. This award highlights Alignment's consistent commitment to medication safety, adherence, and high-quality pharmacy care for seniors.
Alignment Health Plan Recognized as One of Four Medicare Advantage Prescription Drug Plans in the U.S. for 2026 Excellence in Quality
Alignment Health Plan has been recognized by the Pharmacy Quality Alliance (PQA) as one of only four Medicare Advantage prescription drug (MAPD) plans in the U.S. to receive the 2026 Excellence in Quality Award. This marks the seventh time Alignment has earned this award, highlighting its commitment to medication safety and adherence for seniors. The award signifies Alignment's perfect 5-star rating on all five PQA medication measures used in CMS's star ratings program.
Wellington affiliates hold 17.1M shares in Alignment Healthcare (ALHC)
Wellington Management affiliates have disclosed a beneficial ownership of 17,098,936 shares, representing an 8.37% stake in Alignment Healthcare (ALHC), as detailed in a Schedule 13G/A SEC filing. This filing indicates shared voting power over 14,895,474 shares among the Wellington entities as of March 31, 2026. The shares are held for clients of Wellington's investment advisers, with no single client owning more than 5% of the class.
Alignment Healthcare Stock To $22?
Alignment Healthcare (ALHC) stock has dropped 26.5% in under a month, from $22.54 to $16.56. Despite historical data showing a -21% median return after similar sharp dips, the company passes basic financial quality checks, and Trefis maintains an Attractive opinion on the stock. The article suggests that while buying the dip can be challenging, staying invested in quality stocks like ALHC through strategies like the Trefis High Quality Portfolio can lead to long-term gains.
1 of 4 Medicare drug plans with perfect scores on 5 medication measures
Alignment Health Plan (NASDAQ: ALHC) has been honored with the 2026 PQA Laura Cranston Excellence in Quality Award, one of only four U.S. Medicare Advantage prescription drug (MAPD) plans to receive this recognition. The award signifies the company's sustained excellence in care delivery and medication adherence, achieving a 4.5-star Part D summary rating and perfect 5-star scores on all five PQA medication measures. This marks Alignment Health Plan's seventh such award, highlighting its commitment to providing high-quality care for seniors.
Alignment Health Plan Recognized as One of Four Medicare Advantage Prescription Drug Plans in the U.S. for 2026 Excellence in Quality
Alignment Healthcare has been recognized by the Pharmacy Quality Alliance (PQA) for excellence in quality for its Medicare Advantage prescription drug (MAPD) plan, one of only four such plans nationally to receive the 2026 Excellence in Quality Award. This marks the seventh time Alignment has received this award, highlighting its commitment to medication safety, adherence, and personalized care for seniors. The recognition is based on achieving a 5-star rating across five specific PQA medication measures, reinforcing the company's efforts to improve health outcomes for its members.
Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives Average Recommendation of "Moderate Buy" from Brokerages
Alignment Healthcare, Inc. (NASDAQ:ALHC) has received a "Moderate Buy" rating from brokerages, with an average 1-year price target of $24.60. The company recently surpassed earnings expectations, reporting $0.05 EPS against a $0.01 consensus and a 33.3% year-over-year revenue increase to $1.24 billion. Despite positive analyst sentiment and strong quarterly results, insiders have engaged in significant share sales totaling approximately $29.6 million over the past 90 days.
Alignment Healthcare, Inc.(NasdaqGS: ALHC) added to S&P 1000
Alignment Healthcare, Inc. (NasdaqGS: ALHC), a company focused on improving healthcare for seniors, has been added to the S&P 1000 index. This announcement follows recent executive changes and the company's presentation at the Bank of America Global Healthcare Conference. UBS also recently adjusted its price target for Alignment Healthcare to $22, maintaining a neutral rating.
Alignment Healthcare Backs Q2 Outlook as Stable Costs, New Markets Lift Margin Hopes
Alignment Healthcare (NASDAQ: ALHC) is reaffirming its Q2 outlook, citing stable medical costs, strong first-half operating improvements, and clear visibility into utilization. The company expects significant margin opportunities as it expands beyond California into more profitable Medicare Advantage segments, which are anticipated to mature over time. Additionally, Alignment Healthcare foresees long-term benefits from integrating technology and AI to enhance workflows, reduce costs, and achieve a 5% to 6% margin.
Alignment Healthcare Elevates Founder John Kao to Chairman
Alignment Healthcare has appointed its founder and CEO, John Kao, as the new chairman of the board, consolidating strategic leadership for future growth. Joseph Konowiecki will now serve as vice chairman and executive vice president of corporate affairs, while Mark Kent assumes the role of president of the management services organization and Shane Hochradel becomes chief operations officer. These changes are designed to fortify operations, enhance provider support, and boost enterprise execution for sustained expansion and shareholder value.
Alignment Healthcare, Inc.(NasdaqGS: ALHC) added to S&P 600 Health Care
Alignment Healthcare, Inc. (NasdaqGS: ALHC) has been added to the S&P 600 Health Care index, with the announcement made on May 13, 2026. This inclusion is part of a broader upgrade in its S&P index presence, as the company was also added to the S&P 1000 CI and S&P Composite 1500 CI around the same time. The news follows recent leadership team strengthening and a presentation at a major healthcare conference.
Alignment Healthcare (ALHC) CEO-linked trust sells 298K shares in open-market trades
Alignment Healthcare CEO John E. Kao's trust sold 298,000 shares of ALHC common stock on May 11, 2026, through open-market transactions. The sales were executed at weighted-average prices of $16.8494 and $17.5350 per share, ranging from $16.22 to $17.70. Following these transactions, the trust holds 1,508,641 indirect shares, while Kao also retains 1,784,868 direct shares, with a Rule 10b5-1 plan adopted on November 21, 2025, noted.
Alignment Healthcare CEO John Kao adds chairman role
Alignment Healthcare (NASDAQ: ALHC) has announced that founder and CEO John Kao will also take on the role of Chairman of the Board. This leadership change also involves Joseph Konowiecki moving to Vice Chairman and Executive Vice President of Corporate Affairs, and the company bringing in Mark Kent as President of its Management Services Organization and Shane Hochradel as Chief Operations Officer. Despite recent stock declines, the company reported strong financial performance with significant revenue growth and expects continued profitability.
Alignment Healthcare Names John Kao Chairman, Shane Hochradel COO
Alignment Healthcare has appointed John Kao as its new Chairman and Shane Hochradel as Chief Operating Officer. The article also briefly mentions Unity Software's Q4 financial results, with revenue increasing 35% year-over-year to $609 million, exceeding analyst estimates, despite reporting a quarterly loss of 66 cents per share.
Alignment Healthcare CEO John Kao adds chairman role
Alignment Healthcare (NASDAQ:ALHC) has announced that founder and CEO John Kao will also serve as Chairman of the Board, with former Chairman Joseph Konowiecki transitioning to Vice Chairman and EVP of Corporate Affairs. The company also appointed Mark Kent as President of its Management Services Organization and Shane Hochradel as Chief Operations Officer. This leadership restructuring comes as the company maintains a strong financial position and despite a 13% decline in year-to-date share performance, analysts predict continued profitability.
Alignment Healthcare CEO Adds Chairman Role As Medicare Business Grows
Alignment Healthcare CEO John Kao is taking on the additional role of chairman as the company expands its Medicare Advantage business and strengthens its management team. This move comes as Alignment Healthcare has turned profitable despite rising medical expenses, with its medical benefit ratio outperforming many rivals. The company also announced other key appointments, including a new vice chairman and additions to its management services organization and operations teams, as it prepares to join the S&P SmallCap 600.
Press Release: Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation
Alignment Healthcare has announced strategic changes to its leadership team, effective immediately, aiming to strengthen its focus on clinical delivery, product innovation, and market expansion. Dawn Maroney has been appointed President, leading all markets, with plans to hire a new Chief Operating Officer. The restructuring is designed to enhance profitability and shareholder value through improved operational efficiency and growth initiatives.
Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation
Alignment Healthcare has announced significant leadership team changes aimed at strengthening the organization for long-term growth. Founder and CEO John Kao has also been named Chairman of the Board, while Joseph Konowiecki will serve as Vice Chairman and EVP of Corporate Affairs. Additionally, Mark Kent joins as President of the MSO, and Shane Hochradel as Chief Operations Officer, reporting directly to Kao.
Alignment Healthcare strengthens leadership team to support long-term growth and shareholder value creation
Alignment Healthcare has strengthened its leadership team to support long-term growth and increase shareholder value. This includes the appointment of John Kao as Chairman and Shane Hochradel as COO. The healthcare platform aims to improve the healthcare experience for seniors through its consumer-centric model.
Alignment Healthcare CEO John Kao adds chairman role By Investing.com
Alignment Healthcare has announced that its founder and CEO, John Kao, will take on the additional role of Chairman of the Board. This restructuring also includes Joseph Konowiecki becoming Vice Chairman and Executive Vice President of Corporate Affairs, and new appointments for Mark Kent as President of MSO and Shane Hochradel as COO. Despite a 13% year-to-date decline in share price, the company maintains a strong financial foundation with impressive revenue growth and analysts predict continued profitability.
Alignment Healthcare, Inc. announces significant enhancements to its leadership team, aiming to provide solid support for the company's long-term growth strategy and to continuously drive shareholder value creation.
Alignment Healthcare, Inc. is enhancing its leadership team to support its long-term growth strategy and boost shareholder value. By bringing in new management talent and optimizing existing team structures, the company aims to strengthen its position in the competitive healthcare market. This move is intended to build a more solid foundation for future business expansion and improved financial performance.
Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation
Alignment Healthcare has announced significant leadership team changes to support long-term growth and shareholder value. Founder and CEO John Kao will also serve as Chairman of the Board, while Joseph Konowiecki transitions to Vice Chairman and EVP of Corporate Affairs. The company also adds Mark Kent as President of its Management Services Organization and Shane Hochradel as Chief Operations Officer to bolster its operational capabilities and strategic positioning.
[8-K] Alignment Healthcare, Inc. Reports Material Event
Alignment Healthcare, Inc. (NASDAQ: ALHC) announced significant leadership and governance changes, detailed in an 8-K filing. Founder and CEO John Kao has been appointed Chairman of the Board, while former Chairman Joseph Konowiecki transitions to Vice Chairman and Executive Vice President of Corporate Affairs. The company also appointed Mark Kent as President of its Management Services Organization and Shane Hochradel as Chief Operations Officer to strengthen its operational and strategic capabilities.
Why Is Alignment Healthcare (ALHC) Stock Rocketing Higher Today
Shares of Alignment Healthcare (ALHC) surged 7.8% after the announcement that the company will join the S&P SmallCap 600 index, replacing Sun Country Airlines Holdings starting May 14. Inclusion in such an index typically boosts a stock's demand as index funds and ETFs are required to purchase shares. Despite this positive news, ALHC stock is down 8.8% year-to-date and is trading 22.5% below its 52-week high.
Alignment Healthcare (ALHC) Climbs 7% Ahead of Business Updates
Alignment Healthcare (ALHC) saw its stock climb by 7.11% as investors anticipated business updates from an upcoming health conference. The company also announced leadership changes, with John Kao taking on the role of Chairman in addition to CEO, and Shane Hochradel joining as the new Chief Operations Officer. These developments are expected to maintain strategic continuity during the company's next phase of growth.
[144] Alignment Healthcare, Inc. SEC Filing
Alignment Healthcare, Inc. (ALHC) filed a Form 144, disclosing proposed and recent sales of Common Stock. The filing details 596,000 pre-IPO shares and lists several sales in March-April 2026, including 250,000 shares sold on April 7, 2026, for over $5.2 million. These transactions were executed under a 10b5-1 Sales Plan and by an individual.
Alignment Healthcare (ALHC) Is Down 19.0% After Turning Profitable And Issuing 2026 Revenue Outlook - Has The Bull Case Changed?
Alignment Healthcare (ALHC) recently reported a move to profitability in Q1 2026 and issued positive revenue guidance for the remainder of the year. While this improved earnings visibility supports the investment narrative, risks related to Medicare Advantage funding and regulatory changes remain. The company's digital initiatives, including the appointment of a Chief Digital Officer, aim to leverage technology to reduce costs and maintain growth amidst potential challenges.
Voya Small Company Portfolio's Alignment Healthcare Inc(ALHC) Holding History
Voya Small Company Portfolio holds 189,758 shares of Alignment Healthcare Inc (ALHC), valued at $3.75 million, representing 1.91% of its portfolio. The fund has made 6 purchases and 7 sales of ALHC since 2022Q4, with an estimated gain of $435,443.12 on its current holdings. This report details the transaction history and the current valuation of ALHC within the Voya Small Company Portfolio.
Alignment Healthcare Down Over 12%, on Pace for Largest Percent Decrease Since October 2024 -- Data Talk
Alignment Healthcare (ALHC) shares dropped over 12% in mid-day trading, putting it on track for its largest single-day percentage decline since October 2024. The stock also saw a significant increase in trading volume, indicating strong investor reaction to the downturn.
A Look At Alignment Healthcare (ALHC) Valuation After Profitable Q1 And Raised Full‑Year Guidance
Alignment Healthcare (ALHC) reported a profitable first quarter with strong revenue and net income, exceeding expectations and raising full-year guidance. Despite recent share price volatility, the company shows strong long-term growth and is considered undervalued by analysts, trading at a discount to both the average analyst target and intrinsic value estimates. This valuation is supported by its technology-enabled care model, efforts to reduce SG&A, and expansion into new markets, although potential changes in Medicare Advantage policies and competition pose risks.
Alignment Healthcare (ALHC) TTM Profitability Milestone Tests Bullish Growth Narratives
Alignment Healthcare (ALHC) has achieved profitability on a trailing twelve-month (TTM) basis, reporting US$19.8m in profit for Q1 2026 after previous losses, with revenue reaching US$4.3b TTM. This milestone supports bullish views on earnings growth, though quarterly fluctuations highlight sensitivity to margins and costs. The stock trades at a P/S of about 1x, below its peer average and analyst targets, indicating potential value despite inherent risks in the healthcare sector.
Alignment Healthcare (ALHC) Is Up 8.2% After Q1 Turn to Profitability and Raised 2026 Outlook – Has The Bull Case Changed?
Alignment Healthcare (ALHC) recorded a significant turnaround in Q1 2026, achieving profitability with net income of US$11.42 million and raising its full-year revenue guidance to US$5.18 billion. This positive performance reinforces the company's tech-enabled Medicare Advantage model, suggesting improving scale and operating leverage, though investors are cautioned about potential regulatory changes. The strong results and a recent equity offering provide flexibility for continued investment, but investors should weigh these positives against potential policy shifts and existing analyst forecasts.
Alignment Healthcare, Inc. (NASDAQ:ALHC) Q1 2026 Earnings Call Transcript
Alignment Healthcare, Inc. (NASDAQ:ALHC) reported strong Q1 2026 results, exceeding guidance with 31% membership growth, 33% revenue growth, and an 88% increase in adjusted EBITDA. The company highlighted ongoing investments in automation and AI to improve efficiency and scalability, expressing confidence in achieving its long-term goal of 1 million members while adapting to Medicare Advantage policy changes.
Alignment Healthcare (ALHC) Gets a Hold from Barclays
Barclays analyst Andrew Mok CFA maintained a Hold rating on Alignment Healthcare (ALHC) and set a price target of $19.00. The analyst consensus for ALHC is a Strong Buy with an average price target of $25.60, despite the company reporting a GAAP net loss of $11.01 million on quarterly revenue of $1.01 billion. Corporate insider sentiment for ALHC is negative, with an increase in insider selling.
ALHC Stock Pulls Back As Traders Eye Key Support
Alignment Healthcare Inc. (ALHC) stock is experiencing a pullback due to regulatory reimbursement concerns, trading down by -12.76%. Despite fast-scaling revenue and a strong cash position, the company faces negative profitability metrics and an aggressive valuation, leading to high volatility. Traders are closely watching key support and resistance levels for potential bounces or breakdowns.
UBS Adjusts Price Target on Alignment Healthcare to $22 From $21, Maintains Neutral Rating
UBS has adjusted its price target for Alignment Healthcare (ALHC) to $22, up from $21, while maintaining a Neutral rating on the stock. This update reflects the analyst's latest assessment of the company's valuation. The report was published early on May 1, 2026.
ALHC Stock Slides From Highs As Traders Watch Support
Alignment Healthcare Inc. (ALHC) stock has seen a significant slide after earnings revealed persistent losses and weaker-than-expected guidance, sending shares down 12.95% from recent highs above $22. Despite robust revenue growth exceeding $1.23 billion quarterly and strong operating cash flow of $128.7 million, the company's thin margins and fragile profitability are concerning traders. The article highlights that traders are now closely watching the $18–$19 support zone as a potential bounce area, emphasizing the importance of price action and disciplined trading strategies in this volatile market.
